Merck's strong drug pipeline, oncology leadership, and 3.8% dividend yield make it a top long-term investment pick. Learn ...

Merck increased its revenue from $39.5 billion in FY 2015 to $64.2 billion in FY 2024. That’s a compound annual growth rate ...

Merck maintains a structured operational model across healthcare and pharmaceutical products, with active research, ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly ...

Rowan University and Merck Animal Health are teaming up to bring veterinary care to more communities across New Jersey. The ...

Merck recently showcased significant advancements by unveiling positive results from its Phase 3 STRIDE-13 Trial of the CAPVAXIVE vaccine, signaling progress in vaccine innovation. Over the past month ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff. The pharmaceutical leader has made an agreement to acquire the COPD ...

Merck recently announced positive topline results from the Phase 3 CORALreef Lipids trial, which contributed to the company's 7% share price rise over the last quarter. This trial confirmed the ...

The Merck Manual – Professional Version is an excellent resource for medical professionals. The app includes an extensive list of medical topics, ranging from clinical pharmacology to gastrointestinal ...

Merck & Company, Inc. (NYSE:MRK) is one of the top 10 mega-cap stocks to buy according to hedge funds. On September 2, Merck & Company (NYSE:MRK) shared early results from a study called CORALreef ...

Dec 16 (Reuters) - Merck (MRK.N), opens new tab said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials. The pharmaceutical giant's ...